title: The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients.
abstract: BACKGROUND
  Visceral hypersensitivity to distension is thought to play an important role in the pathophysiology of the irritable bowel syndrome (IBS). Cannabinoids are known to decrease somatic pain perception, but their effect on visceral sensitivity in IBS remains unclear. Therefore, we evaluated the effect of the mixed CB(1) /CB(2) receptor agonist delta-9-tetrahydrocannabinol (Δ(9) -THC, dronabinol) on rectal sensitivity.
  
  
  METHODS
  Ten IBS patients and 12 healthy volunteers (HV) underwent a barostat study to assess rectal sensitivity using an intermittent pressure-controlled distension protocol before and after sigmoid stimulation. Repetitive sigmoid stimulation is a validated method to increase visceral perception in IBS patients, consisting of a 10-min period of 30 s stimuli (60 mmHg), separated by 30 s of rest (5 mmHg). The effect of placebo and Δ(9) -THC (5 and 10 mg in healthy volunteers and 10 mg in IBS patients) on rectal sensitivity was evaluated on respectively three and two separate days in a double blind, randomized, crossover fashion.
  
  
  RESULTS
  All participants (HV and IBS) reported central side effects during the highest dose of Δ(9) -THC, most frequently increased awareness of the surrounding, light-headedness and sleepiness, whereas no side effects where reported during placebo. Although blood pressure was not affected, heart rate increased in both HV and IBS, but was most pronounced in IBS patients. The cannabinoid agonist Δ(9) -THC did not alter baseline rectal perception to distension compared to placebo in HV or IBS patients. Similarly, after sigmoid stimulation there were no significant differences between placebo and Δ(9) -THC in sensory thresholds of discomfort.
  
  
  CONCLUSIONS
  These findings imply that Δ(9) -THC does not modify visceral perception to rectal distension and argue against (centrally acting) CB agonists as tool to decrease visceral hypersensitivity in IBS patients.
authors: Department of Gastroenterology and Hepatology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.
authors: T K
authors: TK
authors: Klooker
authors: K E M
authors: KE
authors: Leliefeld
authors: R M
authors: RM
authors: Van Den Wijngaard
authors: G E E
authors: GE
authors: Boeckxstaens
mesh_terms: D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000494:pharmacology / Q000627:therapeutic use; D063386:Cannabinoid Receptor Agonists; D018592:Cross-Over Studies; D004108:Dilatation, Pathologic / Q000188:drug therapy / Q000503:physiopathology; D004311:Double-Blind Method; D013759:Dronabinol / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006930:Hyperalgesia / Q000503:physiopathology; D043183:Irritable Bowel Syndrome / Q000188:drug therapy / Q000503:physiopathology; D008875:Middle Aged; D017288:Pain Threshold / Q000187:drug effects; D010919:Placebos / Q000627:therapeutic use; D011312:Pressure; D012007:Rectum / Q000187:drug effects / Q000503:physiopathology; D014781:Viscera / Q000187:drug effects* / Q000294:innervation; D055815:Young Adult
chemical_list: D018712:Analgesics, Non-Narcotic; D063386:Cannabinoid Receptor Agonists; D010919:Placebos; D013759:Dronabinol